Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy

NCT03905512 is registered in ClinicalTrials.gov with Selecta Biosciences, Inc. as lead sponsor.

NCT NCT03905512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03905512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy
Lead sponsor
Selecta Biosciences, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 7, 2019
Completion date
August 5, 2020
Enrollment
170 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

chronic gout